共 181 条
[21]
Weickhardt A(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1823
[22]
Eggener S(2015)Cabozantinib versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1814-3858
[23]
Yossepowitch O(2017)Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the checkmate 016 study J Clin Oncol 35 3851-1482
[24]
Pettus J(2015)Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Lancet Oncol 16 1473-283
[25]
Snyder M(2016)Outcome and safety of Sorafenib in metastatic renal cell carcinoma Dialysis patients: a systematic review Clin Genitourin Cancer 14 277-86
[26]
Motzer R(2013)Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma Int J Clin Oncol 18 81-754
[27]
Russo P(2012)Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study Med Oncol 29 750-4474
[28]
Tafreshi A(2009)Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 4469-1913
[29]
Thientosapol E(2012)Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol 29 1908-183
[30]
Liew M(2018)Adjuvant therapies in nonmetastatic renal-cell carcinoma: a review of the literature Clin Genitourin Cancer 16 176-16